"Under the terms of the agreement, OXIS receives exclusive rights to conduct researc h to develop, make, use, sell, and import
DT2219ARL worldwide for the treatment of any disease, state or condition in humans. OXIS shall own all permits, licenses,
authorizations, registrations and regulatory approvals required." license issued.

Check out the filing here:

http://filings.irdirect.net/data/109657/00009...icense.pdf